Skip to content
10-Q

Quarterly Report

KALARIS THERAPEUTICS, INC. KLRS

0000950170-25-071339

← back to feed
Filed
May 14, 2025 12:00 AM ET
Period of report
Restated figures. One or more values in this filing restate previously reported amounts.

On SEC.gov

Financials in this filing

Metric Period Value
Shares Outstanding Q1 2025 · May 7, 2025 18.7M sh
Current Liabilities Q1 2025 · Mar 31, 2025 $7.14M
Current Liabilities Q1 2025 · Dec 31, 2024 $24.7M
Total Liabilities Q1 2025 · Mar 31, 2025 $39.22M
Total Liabilities Q1 2025 · Dec 31, 2024 $56.78M
Current Assets Q1 2025 · Mar 31, 2025 $102.18M
Current Assets Q1 2025 · Dec 31, 2024 $2.61M
Total Assets Q1 2025 · Mar 31, 2025 $103.09M
Total Assets Q1 2025 · Dec 31, 2024 $6.16M
Cash And Equivalents Q1 2025 · Dec 31, 2024 $1.64M
Cash And Equivalents restated Q1 2025 · Mar 31, 2024 $5.23M
Rd Expense Q1 2025 · Aug 31, 2024 $100K
Rd Expense restated Q1 2025 · Mar 31, 2024 $1.96M
Shares Diluted restated Q1 2025 · Mar 31, 2024 1.31M sh
Operating Cash Flow restated Q1 2025 · Mar 31, 2024 −$4.52M
Stockholders Equity restated Q1 2025 · Mar 31, 2024 −$47.54M
Stockholders Equity restated Q1 2025 · Dec 31, 2023 −$45.02M
Eps Diluted restated Q1 2025 · Mar 31, 2024 −$2.60
Eps Basic restated Q1 2025 · Mar 31, 2024 −$2.60
Sga Expense restated Q1 2025 · Mar 31, 2024 $602K
Net Income restated Q1 2025 · Mar 31, 2024 −$3.41M
Operating Income restated Q1 2025 · Mar 31, 2024 −$2.56M